Guideline update presents 9 recommendations for antiviral treatment in adults with mild to moderate COVID-19, implying improved management strategies.
This article provides a focused update to the clinical practice guideline on the treatment and management of people with COVID-19, developed by the Infectious Diseases Society of America. The guideline panel presents 9 updated recommendations on the use of nirmatrelvir/ritonavir, remdesivir, and molnupiravir, in adults with mild to moderate COVID-19. The recommendations are based on evidence derived from a systematic literature review and adhere to a standardized methodology for rating the certainty of evidence and strength of recommendation according to the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) approach. The panel also provides a section on how to apply these recommendations, including an algorithm on the selection of antivirals.
No takes yet. Share an insight, caveat, or question.
Shumaker et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: